Skip to main content
    D

    DarioHealth Corp (DRIO)

    Official site

    HEALTHCARE • HEALTH INFORMATION SERVICES • NASDAQ

    $1.15
    -0.11 (-8.73%)

    Market Cap: $14.22M

    Last updated: Nov 17, 2026 at 10:57 AM ET

    DarioHealth Corp (DRIO) Earnings: Report Dates and Results

    Updated Nov 12, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    DarioHealth (DRIO) is expected to report earnings on Mar 17, 2027. In the quarter ended Sep 30, 2026, DarioHealth reported EPS of -$0.73, below the -$0.68 estimate. It beat the EPS estimate in 4 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    48%(19/40)
    Avg Surprise
    -28.41%

    Upcoming Estimates

    Reports Mar 17, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.62
    RangeN/A
    5 analysts
    Revenue Consensus
    $5.55M
    Range$5.19M - $5.92M
    6 analysts

    Next Report

    DRIO has an expected report date of Mar 17, 2027.

    DRIO Earnings Call

    The latest DRIO earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, DRIO beat 19 and missed 21. Revenue for the quarter ended Sep 30, 2026 was $5.31M, up 6.0% from $5.01M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.73-$0.68N/A-7.35%MissN/A21 up, 0 downNov 12, 2026$5.31M
    Jun 30, 2026-$0.85-$1.19N/A+28.57%BeatN/A20 up, 1 downAug 11, 2026$5.18M
    Mar 31, 2026-$0.95-$0.85-$0.99 - -$0.71-11.76%MissN/A21 up, 0 downMay 13, 2026$5.58M
    Dec 31, 2025-$0.77-$1.59-$1.97 - -$1.16+51.86%BeatN/A30 up, 1 downMar 19, 2026$5.23M
    Sep 30, 2025-$2.22-$2.42-$3.60 - -$1.65+8.26%BeatN/A30 up, 1 downNov 13, 2025$5.01M
    Jun 30, 2025-$4.09-$2.07-$2.40 - -$1.80-97.58%MissN/A30 up, 1 downAug 12, 2025$5.37M
    Mar 31, 2025-$2.38-$1.10-$1.40 - -$0.80-116.36%Miss-355.9%20 up, 0 downMay 14, 2025$6.75M
    Dec 31, 2024-$0.04-$0.23N/A+80.90%BeatN/A20 up, 0 downMar 10, 2025$7.60M
    Sep 30, 2024-$3.67-$3.60-$7.00 - -$3.20-1.94%MissN/A30 up, 0 downNov 7, 2024$7.42M
    Jun 30, 2024-$4.06-$5.80N/A+30.00%BeatN/A20 up, 0 downAug 8, 2024$6.25M
    Mar 31, 2024$0.93-$7.40-$11.80 - -$4.40+112.57%BeatN/A21 up, 0 downMay 15, 2024$5.76M
    Dec 31, 2023-$0.50-$0.55N/A+9.09%BeatN/A20 up, 0 downMar 28, 2024$3.62M
    Sep 30, 2023-$6.48-$6.40-$12.00 - -$5.00-1.25%MissN/A41 up, 0 downNov 2, 2023$3.52M
    Jun 30, 2023-$8.34-$6.00N/A-39.00%MissN/A50 up, 0 downAug 10, 2023$6.15M
    Mar 31, 2023-$4.90-$7.40N/A+33.78%BeatN/A50 up, 0 downMay 11, 2023$7.07M
    Dec 31, 2022-$0.51-$0.65-$0.92 - -$0.47+21.54%BeatN/A52 up, 0 downMar 9, 2023$6.81M
    Sep 30, 2022-$8.25-$11.40N/A+27.63%BeatN/A70 up, 0 downNov 14, 2022$6.61M
    Jun 30, 2022-$14.15-$10.40N/A-36.06%MissN/A81 up, 0 downAug 15, 2022$6.18M
    Mar 31, 2022-$17.05-$14.70N/A-15.99%MissN/A70 up, 0 downMay 12, 2022$8.06M
    Dec 31, 2021-$1.09-$1.06-$1.35 - -$0.59-2.83%MissN/A7N/AMar 22, 2022$6.03M
    Sep 30, 2021-$14.98-$15.67N/A+4.40%BeatN/A6N/ANov 15, 2021$5.63M
    Jun 30, 2021-$17.95-$13.56N/A-32.37%MissN/A6N/AAug 16, 2021$5.26M
    Mar 31, 2021-$0.92-$1.04-$2.50 - -$0.59+11.54%BeatN/A6N/AMay 17, 2021$3.60M
    Dec 31, 2020-$21.20-$18.12-$19.00 - -$12.40-17.00%MissN/A5N/AMar 9, 2021$2.08M
    Sep 30, 2020-$14.20-$12.10-$16.80 - -$11.20-17.36%MissN/A3N/ANov 12, 2020$2.04M
    Jun 30, 2020-$13.60-$30.30-$38.00 - -$20.40+55.12%BeatN/A4N/AAug 12, 2020$1.79M
    Mar 31, 2020-$31.40-$7.80-$22.20 - -$7.80-302.56%MissN/A2N/AMay 12, 2020$1.67M
    Dec 31, 2019-$7.72-$1.02-$1.20 - -$0.84-656.86%MissN/A2N/AMar 17, 2020$1.80M
    Sep 30, 2019-$24.00-$40.00-$40.00 - -$32.00+40.00%BeatN/A2N/AOct 28, 2019$1.87M
    Jun 30, 2019-$2.60-$2.70N/A+3.70%BeatN/A2N/AAug 13, 2019$1.65M
    Mar 31, 2019-$60.00-$52.00-$52.00 - -$52.00-15.38%MissN/A1N/AMay 13, 2019$2.24M
    Dec 31, 2018-$2.20-$3.00N/A+26.67%BeatN/AN/AN/AMar 25, 2019$1.70M
    Sep 30, 2018-$3.40-$3.60N/A+5.56%BeatN/AN/AN/ANov 13, 2018$1.88M
    Jun 30, 2018-$128.00-$72.00N/A-77.78%MissN/AN/AN/AAug 9, 2018$2.06M
    Mar 31, 2018-$80.00-$68.00-$84.00 - -$68.00-17.65%Miss-17877.8%2N/AMay 15, 2018$1.76M
    Dec 31, 2017-$25.20-$6.00-$6.00 - -$6.00-320.00%MissN/A1N/AMar 19, 2018$1.58M
    Sep 30, 2017-$120.00-$122.00N/A+1.64%BeatN/AN/AN/ANov 14, 2017$1.38M
    Jun 30, 2017-$172.00-$120.00N/A-43.33%MissN/AN/AN/AAug 14, 2017$1.21M
    Mar 31, 2017$0.45-$0.30N/A+250.00%BeatN/AN/AN/AMay 15, 2017$1.01M
    Dec 31, 2016-$384.00-$184.00N/A-108.70%MissN/AN/AN/AMar 22, 2017$838000
    Last 40 quarters

    Estimates made before a stock split are shown on the same share basis as the reported EPS.

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$9.46, after -$6.84 the year before. It was -$836.00 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$9.46N/A
    Dec 31, 2024-$6.84N/A
    Dec 31, 2023-$20.22N/A
    Dec 31, 2022-$39.96N/A
    Dec 31, 2021-$34.94N/A
    Dec 31, 2020-$80.40N/A
    Dec 31, 2019-$94.32N/A
    Dec 31, 2018-$213.60N/A
    Dec 31, 2017-$316.75N/A
    Dec 31, 2016-$836.00N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 7,800 words across 10 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20267,79010
    2026Q2Jun 30, 20265,0277
    2026Q1Mar 31, 20264,8326
    2025Q4Dec 31, 20255,3097
    2025Q3Sep 30, 20255,4738
    2025Q2Jun 30, 20254,7017
    2025Q1Mar 31, 20255,6216
    2024Q4Dec 31, 20245,2467

    2026Q3 Earnings Call

    Opening remarks

    Zoe Harrison VP, Accounting and Corporate Development Thank you, operator, and good morning, everyone. Thank you for joining us today for a discussion of DarioHealth's Third Quarter of 2026 Financial Results. Leading the call today will be Erez Raphael, Chief Executive Officer of DarioHealth. He'll be followed by John Palumbo, Chairman of the Board; Lara Dodo, our Chief Operating Officer; and Chen Franco, our Chief Financial Officer. An audio recording and webcast replay for today's call will also be available online, as detailed in the press release invite for this call. For the benefit of those who may be listening to the replay or archived webcast, this call is being held on Thursday, November 12, 2026. This morning, we issued a press release announcing our financial results for the third quarter of 2026. A copy of the release can be found on the Investor Relations page of DarioHealth's website. I'd like to remind you that on this call, management will make forward-looking statements within the meaning of the federal securities laws. For example, the company is using forward-looking statements when it discusses expected revenue growth and contribution from signed accounts, the timing and extent of revenue recognition under existing customer agreements, the company's revenue outlook and financial performance expectations, its path to profitability and positive cash flow, the continued reduction in operating expenses and losses, its expansion of channel partnerships and distribution, expected revenue and scaling from partner-led opportunities, expected onboarding, implementation and enrollment of large enterprise accounts, expected conversion of contracted annual recurring revenue into recognized revenue, expected expansion into care delivery, claims-based and outcomes-based models, expected benefit from care delivery partnerships, expected growth in recurring revenue and operating leverage, expected advantages and future impact of DarioIQ and proprietary data assets, expected improvements in member engagement, retention and outcomes, the anticipated benefits of artificial intelligence across the company's commercial operations and internal operations, including expected cost savings, productivity improvements and potential incremental revenue opportunities, the anticipated expansion of existing customer relationships into additional chronic conditions, the expected timing and contribution of new product offerings, the company's ability to increase revenue per customer through its multi-condition strategy, the expected benefits of provider-backed clinical care, the expected timing of revenue acceleration and of activation under health plan agreements, beliefs regarding the convergence of consumer and payer-funded health care and the replatforming of chronic care management, the expected delivery of GLP-1 and other therapies within payer programs and marketplaces, the expected contribution of women's and men's health programs, and beliefs regarding competitive positioning and market opportunity. Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond the company's control, including the risks described from time to time in its SEC filings.

    Frequently Asked Questions About DRIO

    When is DarioHealth's next earnings date?

    DarioHealth's next earnings report is expected for Mar 17, 2027.

    Did DRIO beat earnings estimates last quarter?

    No. DarioHealth reported EPS of -$0.73 for the quarter ended Sep 30, 2026, below the -$0.68 estimate by 7.35%.

    What EPS do analysts expect from DRIO next quarter?

    The consensus EPS estimate for DarioHealth for the quarter ending Dec 31, 2026 is -$0.62 from 5 analysts.

    How often does DRIO beat earnings estimates?

    DarioHealth beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of -7.93%.